Literature DB >> 23188108

EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia.

Christopher T Gordon1, Florence Petit, Myriam Oufadem, Charles Decaestecker, Anne-Sophie Jourdain, Joris Andrieux, Valérie Malan, Jean-Luc Alessandri, Geneviève Baujat, Clarisse Baumann, Odile Boute-Benejean, Roseline Caumes, Bruno Delobel, Klaus Dieterich, Dominique Gaillard, Marie Gonzales, Didier Lacombe, Fabienne Escande, Sylvie Manouvrier-Hanu, Sandrine Marlin, Michèle Mathieu-Dramard, Sarju G Mehta, Ingrid Simonic, Arnold Munnich, Michel Vekemans, Nicole Porchet, Loïc de Pontual, Sabine Sarnacki, Tania Attie-Bitach, Stanislas Lyonnet, Muriel Holder-Espinasse, Jeanne Amiel.   

Abstract

BACKGROUND: Oesophageal atresia (OA) and mandibulofacial dysostosis (MFD) are two congenital malformations for which the molecular bases of syndromic forms are being identified at a rapid rate. In particular, the EFTUD2 gene encoding a protein of the spliceosome complex has been found mutated in patients with MFD and microcephaly (MIM610536). Until now, no syndrome featuring both MFD and OA has been clearly delineated.
RESULTS: We report on 10 cases presenting with MFD, eight of whom had OA, either due to de novo 17q21.31 deletions encompassing EFTUD2 and neighbouring genes or de novo heterozygous EFTUD2 loss-of-function mutations. No EFTUD2 deletions or mutations were found in a series of patients with isolated OA or isolated oculoauriculovertebral spectrum (OAVS).
CONCLUSIONS: These data exclude a contiguous gene syndrome for the association of MFD and OA, broaden the spectrum of clinical features ascribed to EFTUD2 haploinsufficiency, define a novel syndromic OA entity, and emphasise the necessity of mRNA maturation through the spliceosome complex for global growth and within specific regions of the embryo during development. Importantly, the majority of patients reported here with EFTUD2 lesions were previously diagnosed with Feingold or CHARGE syndromes or presented with OAVS plus OA, highlighting the variability of expression and the wide range of differential diagnoses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188108     DOI: 10.1136/jmedgenet-2012-101173

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  39 in total

1.  Copy number variations in 375 patients with oesophageal atresia and/or tracheoesophageal fistula.

Authors:  Erwin Brosens; Florian Marsch; Elisabeth M de Jong; Hitisha P Zaveri; Alina C Hilger; Vera Gisela Choinitzki; Alice Hölscher; Per Hoffmann; Stefan Herms; Thomas M Boemers; Benno M Ure; Martin Lacher; Michael Ludwig; Bert H Eussen; Robert M van der Helm; Hannie Douben; Diane Van Opstal; Rene M H Wijnen; H Berna Beverloo; Yolande van Bever; Alice S Brooks; Hanneke IJsselstijn; Daryl A Scott; Johannes Schumacher; Dick Tibboel; Heiko Reutter; Annelies de Klein
Journal:  Eur J Hum Genet       Date:  2016-07-20       Impact factor: 4.246

2.  Dysregulation of cotranscriptional alternative splicing underlies CHARGE syndrome.

Authors:  Catherine Bélanger; Félix-Antoine Bérubé-Simard; Elizabeth Leduc; Guillaume Bernas; Philippe M Campeau; Seema R Lalani; Donna M Martin; Stephanie Bielas; Amanda Moccia; Anshika Srivastava; David W Silversides; Nicolas Pilon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

3.  SCRIB and PUF60 are primary drivers of the multisystemic phenotypes of the 8q24.3 copy-number variant.

Authors:  Andrew Dauber; Christelle Golzio; Cécile Guenot; Francine M Jodelka; Maria Kibaek; Susanne Kjaergaard; Bruno Leheup; Danielle Martinet; Malgorzata J M Nowaczyk; Jill A Rosenfeld; Susan Zeesman; Janice Zunich; Jacques S Beckmann; Joel N Hirschhorn; Michelle L Hastings; Sebastien Jacquemont; Nicholas Katsanis
Journal:  Am J Hum Genet       Date:  2013-10-17       Impact factor: 11.025

Review 4.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 5.  Review of the Genetic Basis of Jaw Malformations.

Authors:  Mairaj K Ahmed; Xiaoqian Ye; Peter J Taub
Journal:  J Pediatr Genet       Date:  2016-10-12

6.  Structural and numerical changes of chromosome X in patients with esophageal atresia.

Authors:  Erwin Brosens; Elisabeth M de Jong; Tahsin Stefan Barakat; Bert H Eussen; Barbara D'haene; Elfride De Baere; Hannah Verdin; Pino J Poddighe; Robert-Jan Galjaard; Joost Gribnau; Alice S Brooks; Dick Tibboel; Annelies de Klein
Journal:  Eur J Hum Genet       Date:  2014-01-08       Impact factor: 4.246

7.  Phenotype analysis of Polish patients with mandibulofacial dysostosis type Guion-Almeida associated with esophageal atresia and choanal atresia caused by EFTUD2 gene mutations.

Authors:  Robert Smigiel; Natalia Bezniakow; Aleksandra Jakubiak; Michał Błoch; Dariusz Patkowski; Ewa Obersztyn; Maria M Sasiadek
Journal:  J Appl Genet       Date:  2014-11-12       Impact factor: 3.240

8.  EFTUD2 deficiency in vertebrates: Identification of a novel human mutation and generation of a zebrafish model.

Authors:  Brett Deml; Linda M Reis; Sanaa Muheisen; David Bick; Elena V Semina
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-06-27

9.  Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity.

Authors:  Lesly De Arras; Rebecca Laws; Sonia M Leach; Kyle Pontis; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  Genetics       Date:  2013-12-20       Impact factor: 4.562

10.  Large deletions encompassing the TCOF1 and CAMK2A genes are responsible for Treacher Collins syndrome with intellectual disability.

Authors:  Marie Vincent; Corinne Collet; Alain Verloes; Laetitia Lambert; Christian Herlin; Catherine Blanchet; Elodie Sanchez; Séverine Drunat; Jacqueline Vigneron; Jean-Louis Laplanche; Jacques Puechberty; Pierre Sarda; David Geneviève
Journal:  Eur J Hum Genet       Date:  2013-05-22       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.